This fund commits at least 80% of its overall assets, alongside any borrowed capital used for investment, to the securities tracked by its benchmark index. This also includes American and Global Depositary Receipts that are derived from those same index securities. The underlying index itself is specifically designed to provide investors with exposure to exchange-listed companies operating directly within China's biotechnology sector.